In an unprecedented and strategic move, the U.S. Food and Drug Administration (FDA) has granted permission for the temporary import of an unapproved Chinese cancer drug. The decision comes amid a growing shortage of vital cancer drugs in the US, notably cisplatin, a widely used chemotherapy medication. The crisis has prompted the FDA to consider unconventional approaches, and this move stands as testament to that flexibility.
